Breaking News

inVentiv, Aprecia Enter Commercialization Pact

June 5, 2014

inVentiv to launch Aprecia brand and technology platform

inVentiv Health and Aprecia Pharmaceuticals entered an exclusive commercialization alliance for the launch the Aprecia brand and technology platform and initial pharmaceutical products.
Aprecia offers the ZipDose product platform using three-dimensional printing (3DP) technology to create fast-melt products. The company has completed clinical development and expects to file its first NDA with the FDA in 2H14. inVentiv will serve as Aprecia’s exclusive provider of commercialization services in exchange for future royalties on sales.
“Getting medicine into the human body reliably and accurately is both a challenge and an enormous opportunity,” said Don Wetherhold, chief executive officer of Aprecia. “To realize the potential of our technology and move quickly into market, we sought a partner that could execute every phase and function in commercialization, and inVentiv was the obvious choice.”
Michael Griffith, executive vice president of inVentiv Health, said, “We are pleased to have entered into this agreement with Aprecia and are looking forward to introducing their innovative technology platform and their much-needed products. Because of our unmatched expertise of pharmaceutical launches, clients know they can count on inVentiv Health to transform their assets into commercial success.”

blog comments powered by Disqus
  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 20, 2015
    (Based on 2014 Sales, in $U.S. Millions)

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important